Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials

Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials

Objective To review long-term certolizumab pegol (CZP) safety across all approved indications: rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), psoriasis (PSO) and Crohn’s disease (CD).Methods Data were pooled across 49 UCB-sponsored CZP clinical trials (27 RA,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tore K Kvien, Xavier Mariette, Jeffrey R Curtis, Vivian P Bykerk, William J Sandborn, Cécile Gaujoux-Viala, Andrew Blauvelt, Kevin Winthrop, Marc de Longueville, Ivo Huybrechts
Formato: Artículo
Lenguaje:English
Publicado: BMJ Publishing Group 2019-05-01
Colección:RMD Open
Acceso en línea:https://rmdopen.bmj.com/content/5/1/e000942.full

Internet

https://rmdopen.bmj.com/content/5/1/e000942.full

Ejemplares similares